Bioceres Crop Solutions Corp (Biox) Q3 2025 profit sound Highlights: Navigating Challenges …

• Total turnover: 60.6 million US dollars after 84 million US dollars in the previous year.

• Gross profit: 24 million US dollars compared to $ 42.6 million in the same period of the previous year.

• Gross marge: Went back to 39% from 51%, especially due to the lack of syngenta.

• Adapted EBITDA: 9 million US dollars, compared to 21.1 million US dollars in the previous year.

• Cash from operating activities: $ 23.3 million, an improvement of $ 40.7 million in the year.

• Inventory reduction: Reduction of $ 13.5 million in a quarter.

• Claims management of accounts: Brought around 31 million US dollars in cash in cash.

• Total debt: Reduced by $ 13 million by the end of the period.

• Leverage: A little over 4.1 at the end of the quarter.

Appearance date: May 21, 2025

You can find the complete copy of the earnings call in the complete earnings call.

• Bioceres Crop Solutions Corp (NASDAQ: Biox) recorded a significant improvement in cash flow performance over the course of the year by $ 40 million, which was supported in the debt and improvement of cash positions.

• The company received the EPA permit for Rinotec and enabled them to offer a comprehensive suite of biological solutions for pest control and plant health in the most important agricultural markets.

• The turnover of seeds and integrated products increased by 26%, which were due to accelerated sales of HB4 cereals from the existing inventory.

• The company achieved a favorable shift in the product mix in harvest protection, which led to a margin expansion from 38% to 41%.

• Bioceres Crop Solutions Corp (Nasdaq: Biox) successfully reduced its salary statement by 68%, which led to an annualized saving of approximately 5 million dollars.

• The total income for the quarter decreased from $ 84 million in the previous year to $ 60.6 million, especially due to the lack of a significant advance payment of Syngenta.

• The gross profit decreased from $ $ 24 to $ 24 million, with a consolidated gross margin returned from 51% to 39%, which is particularly due to the Syngenta payment of the previous year.

• The Argentine market had a particularly slow third quarter, with the reduced the commercial activities on sales with the inputs.

• The adjusted EBITDA fell from $ 21.1 million in the previous year to 9 million US dollars, which contradicts the lack of Syngenta payment.

• The company is still in a transition period and makes it difficult to give specific guidelines for the future EBITDA for the conversion of cash flows.

Q: Congratulations on cash advancement this quarter. How much of the relaxation of the operating capital is still available and, as expected, EBITDA expects the cash flow conversion over time? A: With HB4 we expect an additional 10 million US dollars from the transition to a lighter model. With regard to the EBITDA to the Free Cashflow conversion, we want to return to the historical level of four to 4.5 months in the operating capital. Our goal is to align EBITDA and the Free Cashflow as precisely as possible and to target around 25% and the gross margins in the high 40s to 1950s as soon as the industry stabilizes.